Breakthrough Status May Not Be So Groundbreaking, Recent Reviews Indicate
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
A look at some of FDA’s novel drug approvals analyzed in Pharmaceutical Approvals Monthly’s 2012 series of drug review profiles suggests that the agency has already ushered through several approvals that could be models for the new “breakthrough” designation created by the FDA Safety and Innovation Act.